Lantheus Medical Imaging
As of the edition of 20 October 2026, Lantheus Medical Imaging runs 11 drugs, 7 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 7 |
| Active | 2 |
| Went quiet | 1 |
| Stopped | 1 |
| Total | 11 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Perflutren | Ends 2035 (patent) | 0 |
| Xenon | none listed | 0 |
| Gadofosveset | none listed | 0 |
| Flurpiridaz | Ends 2029 (exclusivity) | 0 |
| Gallium citrate | none listed | 0 |
| Thallous chloride | none listed | 0 |
| Samarium lexidronam pentasodium | none listed | 0 |
A route B row is one company at one target.
Where its trials are
- Heart and blood vessels: 7 trials led
- Cancer: 3 trials led
- Urinary and reproductive: 2 trials led